Please login to the form below
Aliqopa
This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.
FDA clears Novartis’ new breast cancer drug Piqray
Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and Verastem’s Copiktra (duvelisib) – but so far they have been unable to
Latest news
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently
-
Novartis considers filings for PI3K drug in breast cancer
years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers.
-
Bayer bags speedy US approval for lymphoma drug Aliqopa
The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Aliqopa (copanlisib) has been given a conditional green light as a third-line treatment for patients with relapsed
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
-
Account Supervisor
-
Salary TBC
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
-
Account Director, Medical Education
-
Salary TBC
-
Account Director
-
Salary TBC
-
Account Executive
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
Subscribe to our email news alerts
- The first of many celebrations for Lucid Group at Middlesex House
- FDA advisors say no to empagliflozin in type 1 diabetes
- Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Novartis makes case for NASH candidate tropifexor
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- RWE Blog 3: Is real-world evidence the holy grail
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- BeiGene bags FDA approval for first product Brukinsa in lymphoma
- Amarin wins FDA advisory nod for Vascepa cardiovascular expansion
- Shionogi scores FDA approval for new cUTI antibiotic
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
- Strengthening business competition and reducing anti-competitive practices
- How the CMA is tackling high prices for essential drugs...
Quick links
Infographics
